Community viral load and CD4 count distribution among people living with HIV in a South African township: Implications for treatment as prevention

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 4, 2013, Pages 498-505

  Kranzer, Katharina ^a,b   Lawn, Stephen D ^a,b   Johnson, Leigh F ^b   Bekker, Linda Gail ^a,c   Wood, Robin ^a,c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

ART coverage; Community CD4 count; Community viral load; Prevalence survey; Treatment as prevention

Indexed keywords

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SOUTH AFRICA; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SOUTH AFRICA; VIRAL LOAD; YOUNG ADULT;

EID: 84880224618     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318293ae48     Document Type: Article

References (70)

1. World AIDS Day Report 2011. 2011. Geneva, Switzerland:UBAIDS. Available at:http://issuu.com/unaids/docs/worldaidsday-report-2011/1. Accessed June 1, 2012.
2. Treating 3 Million by 2005:Making It Happen:The WHO Strategy:The WHO and UNAIDS Global Initiative to Provide Antiretroviral Therapy to 3 Million People with HIV/AIDS in Developing Countries by the End of 2005/Treat 3 Million by 2005. 2003. Geneva, Switzerland:World Health Organization. Available at:http://data.unaids.org/Publications/External-Documents/- who-3by5-trategy-en. pdf. Accessed June 26, 2012.
3. Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med. 2009;30:685-699, viii.
4. Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: A longitudinal study. Lancet. 2006;368:1254-1259.
5. Jahn A, Floyd S, Crampin AC, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet. 2008;371:1603-1611.
6. Floyd S, Molesworth A, Dube A, et al. Population-level reduction in adult mortality after extension of free anti-retroviral therapy provision into rural areas in northern Malawi. PLoS One. 2010;5:e13499.
7. Mahy M, Stover J, Stanecki K, et al. Estimating the impact of antiretroviral therapy:regional and global estimates of life-years gained among adults. Sex Transm Infect. 2010;86(suppl 2):ii67-ii71.
8. Global HIV/AIDS Response:Epidemic Update and Health Sector Progress Towards Universal Access. 2011. Geneva, Switzerland:World Health Organization. Available at:http://whqlibdoc.who.int/publications/2011/9789241502986-eng.pdf. Accessed June 3, 2012.
9. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl JMed. 2010;363:257-265.
10. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197:1133-1144.
11. Antiretroviral Therapy for HIV Infection in Adults and Adolescents:Recommendations for a Public Health Approach (2010 version). 2010. Geneva, Switzerland:World Health Organization. Available at:http://whqlibdoc. who.int/publications/2010/9789241599764-eng.pdf. Accessed August 14, 2010.
12. South African Antiretroviral Treatment Guidelines. 2010. Pretoria, South Africa:South African National AIDS Council/Department of Health. Available at:http://www.sanac.org.za/documents/2010%20ART%20Guideline-Short.pdf. Accessed May 25, 2010.
13. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type
14. Rakai project study group. N Engl J Med. 2000;342:921-929.
15. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357:1149-1153.
16. Kumarasamy N, Venkatesh KK, Srikrishnan AK, et al. Risk factors for HIV transmission among heterosexual discordant couples in South India. HIV Med. 2010;11:178-186.
17. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: A mathematical model. Lancet. 2009;373:48-57.
18. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS. 2010;24:729-735.
19. Zachariah R, Harries AD, Philips M, et al. Antiretroviral therapy for HIV prevention:many concerns and challenges, but are there ways forward in sub-aharan Africa? Trans R Soc Trop Med Hyg. 2010;104:387-391.
20. Granich R, Kahn JG, Bennett R, et al. Expanding ART for treatment and prevention of HIV in South Africa:estimated cost and cost-effectiveness 2011-2050. PLoS One. 2012;7:e30216.
21. Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: A modelling study. PLoS Med. 2011;8:e1001123.
22. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
23. Anglemyer A, Rutherford GW, Baggaley RC, et al. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev. DOI:10.1002/14651858.CD009153.
24. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: A population-based study. Lancet. 2010;376:532-539.
25. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5:e11068.
26. Barnighausen T, Tanser F, Dabis F, et al. Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-aharan Africa:The experimental evidence. Curr Opin HIV AIDS. 2012;7:140-150.
27. Connelly D, Veriava Y, Roberts S, et al. Prevalence of HIV infection and median CD4 counts among health care workers in South Africa. S Afr Med J. 2007;97:115-120.
28. Auvert B, Males S, Puren A, et al. Can highly active antiretroviral therapy reduce the spread of HIV? A study in a township of South Africa. J Acquir Immune Defic Syndr. 2004;36:613-621.
29. Rehle TM, Shisana O. Estimates of eligibility for antiretroviral treatment (ART) and projected ART impact on AIDS mortality among South African educators. Sahara J. 2005;2:304-310.
30. Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa:implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006;42:464-469.
31. Kelly P, Zulu I, Amadi B, et al. Morbidity and nutritional impairment in relation to CD4 count in a Zambian population with high HIV prevalence. Acta Trop. 2002;83:151-158.
32. Kranzer K, van Schaik N, Karmue U, et al. High prevalence of selfreported undiagnosed HIV despite high coverage of HIV testing: A cross-ectional population based sero-urvey in South Africa. PLos One. 2011;6:e25244.
33. Western Cape Department of Health. The Western Cape Antiretroviral Programme. 2006. Cape Town, South Africa:Provincial Government of the Western Cape:Western Cape Department of health. Available at:http://web.uct.ac.za/depts/ epi/artrollout/. Accessed February 2, 2011.
34. Sanne I, Orrell C, Fox MP, et al. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-A): A randomised non-inferiority trial. Lancet. 2010;376:33-40.
35. Van Schaik N, Kranzer K, Wood R, et al. Earlier HIV diagnosis-are mobile services the answer? S Afr Med J. 2010;100:671-674.
36. Attia S, EggerM, MullerM, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy:systematic review and meta-analysis. AIDS. 2009;23:1397-1404.
37. Lingappa J.R, Hughes JP, Wang RS, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One. 2010;5:e12598.
38. The Voluntary HIV-1 Counseling and Testing Efficacy Study Group. Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: A randomised trial. Lancet. 2000;356:103-112.
39. Sherr L, Lopman B, Kakowa M, et al. Voluntary counselling and testing:uptake, impact on sexual behaviour, and HIV incidence in a rural Zimbabwean cohort. Aids. 2007;21:851-860.
40. Muller O, Sarangbin S, Ruxrungtham K, et al. Sexual risk behaviour reduction associated with voluntary HIV counselling and testing in HIV infected patients in Thailand. AIDS Care. 1995;7:567-572.
41. Mwangi M, Bunnell R, Nyoka R, et al. Unsafe sex among HIV-infected adults in Kenya:results of a nationally representative survey. J Acquir Immune Defic Syndr. 2011;58:80-88.
42. Castel AD, Befus M, Willis S, et al. Use of the community viral load as a population-based biomarker of HIV burden. AIDS. 2012;26:345-353.
43. Wood E, Kerr T, Marshall BD, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users:prospective cohort study. BMJ. 2009;338:b1649.
44. Jain V, Liegler T, Kabami J, et al. Assessment of population-based HIV RNA levels in a rural East African setting using a fingerprick-based blood collection method. Clin Infect Dis. 2013;56:598-605.
45. Moatti JP, Prudhomme J, Traore DC, et al. Access to antiretroviral treatment and sexual behaviours of HIV-infected patients aware of their serostatus in Cote d'Ivoire. AIDS. 2003;17(suppl 3):S69-77.
46. Dia A, Marcellin F, Bonono RC, et al. Prevalence of unsafe sex with one's steady partner either HIV-negative or of unknown HIV status and associated determinants in Cameroon (EVAL ANRS12-116 survey). Sex Transm Infect. 2010;86:148-154.
47. Venkatesh KK, de Bruyn G, Lurie MN, et al. Decreased sexual risk behavior in the era of HAART among HIV-infected urban and rural South Africans attending primary care clinics. AIDS. 2010;24:2687-2696.
48. Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS. 2006;20:85-92.
49. Muwonga J, Edidi S, Butel C, et al. Resistance to antiretroviral drugs in treated and drug-naive patients in the democratic republic of Congo. J Acquir Immune Defic Syndr. 2011;57(suppl 1):S27-33.
50. El-Khatib Z, Ekstrom AM, Ledwaba J, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: A cross-ectional study in Soweto, South Africa. AIDS. 2010;24:1679-1687.
51. Johannessen A, Naman E, Kivuyo SL, et al. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis. 2009;9:108.
52. Rougemont M, Stoll BE, Elia N, et al. Antiretroviral treatment adherence and its determinants in sub-aharan Africa: A prospective study at Yaounde central hospital, Cameroon. AIDS Res Ther. 2009;6:21.
53. El-Khatib Z, Katzenstein D, Marrone G, et al. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011;6:e17518.
54. Charurat M, Oyegunle M, Benjamin R, et al. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: A longitudinal analysis for risk factors. PLoS One. 2010;5:e10584.
55. Nozaki I, Dube C, Kakimoto K, et al. Social factors affecting ART adherence in rural settings in Zambia. AIDS Care. 2011;23:831-838.
56. Kunutsor S, Evans M, Thoulass J, et al. Ascertaining baseline levels of antiretroviral therapy adherence in Uganda: A multimethod approach. J Acquir Immune Defic Syndr. 2010;55:221-224.
57. Kipp W, Alibhai A, Saunders LD, et al. Gender differences in antiretroviral treatment outcomes of HIV patients in rural Uganda. AIDS Care. 2010;22:271-278.
58. Barth RE, Tempelman HA, Moraba R, et al. Long-term outcome of an HIV-treatment programme in rural Africa:viral suppression despite early mortality. AIDS Res Treat. 2011;2011:434375.
59. Deeks SG, Walker BD. Human immunodeficiency virus controllers:mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 2007;27:406-416.
60. Laeyendecker O, Redd AD, Lutalo T, et al. Frequency of long-term nonprogressors in HIV-1 seroconverters from Rakai Uganda. J Acquir Immune Defic Syndr. 2009;52:316-319.
61. Lawn SD, Little F, Bekker LG, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS. 2009;23:335-342.
62. Lawn SD, Myer L, Edwards D, et al. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS. 2009;23:1717-1725.
63. Remien RH, Chowdhury J, Mokhbat JE, et al. Gender and care:access to HIV testing, care, and treatment. J Acquir Immune Defic Syndr. 2009;51 (suppl 3):S106-110.
64. Muula AS, Ngulube TJ, Siziya S, et al. Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: A systematic review. BMC Public Health. 2007;7:63.
65. Amuron B, Namara G, Birungi J, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009;9:290.
66. Cornell M, Myer L, Kaplan R, et al. The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health. 2009;14:722-731.
67. Johnson LF. Access to antiretroviral treatment in South Africa, 2004-2011. South Afr J HIV Med. 2012;13:22-27.
68. Marston M, Harriss K, Slaymaker E. Non-response bias in estimates of HIV prevalence due to the mobility of absentees in national populationbased surveys: A study of nine national surveys. Sex Transm Infect. 2008; 84(suppl 1):i71-i77.
69. Amornkul PN, Vandenhoudt H, Nasokho P, et al. HIV prevalence and associated risk factors among individuals aged 13-34 years in rural Western Kenya. PLoS One. 2009;4:e6470.
70. Ziraba AK, Madise NJ,Matilu M, et al. The effect of participant nonresponse on HIV prevalence estimates in a population-based survey in two informal settlements in Nairobi city. Popul Health Metr. 2010;8:22.